ClinicalTrials.gg
RecruitingNCT07198321Updated Nov 16, 2026

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

A Phase 1/2 interventional study of GFH276 in Cancer, PDAC and CRC (Colorectal Cancer), sponsored by Genfleet Therapeutics (Shanghai) Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionColorectal NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms
Why
  1. The study's listed conditions name Colorectal Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Genfleet Therapeutics (Shanghai) Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 604 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
102nd of 891
450 · median 80
Started
2025
with 124 others
Phase 1/2
95 of 1,136
44 open now
Primary completion
2027-07
later than 397 of 603 live
Registered
961st of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 102nd largest by planned enrollment of the 891 interventional ones that give a count, is one of 125 that started in 2025, is one of 95 in phase 1/2, reaches primary completion later than 397 of the 603 other live ones, and was the 961st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is an investigation to evaluate the safety/tolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations.

The primary objectives of the Phase I study are to assess the safety/tolerability, PK, and preliminary efficacy of GFH276 in patients with advanced solid tumors harboring RAS mutations, and to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of GFH276.

The primary objective of the Phase II study is to evaluate the efficacy of GFH276 in patients with RAS-mutant advanced pancreatic ductal adenocarcinoma (PDAC), advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC), and other advanced solid tumors.

03

Conditions studied

  • Cancer
  • PDAC
  • CRC (Colorectal Cancer)
  • NSCLC

Browse trials for

Keywords

  • cancer
  • RAS
04

In context

Colorectal Neoplasms Reclassified

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's planned enrollment of 450 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Genfleet Therapeutics (Shanghai) Inc. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.

Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form.
  2. Male or female ≥ 18 years old and ≤75 years old.
  3. performance status of 0-1.
  4. With a of ≥3 moths
  5. Have at least one according to RECIST1.1, and the phase Ia allows no measurable lesion.
  6. Adequate laboratory parameters during the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Active .
  2. Prior treatment with a PAN-RAS inhibitor.
  3. Palliative radiotherapy was completed within 14 days before the first dose.
  4. Have poorly controlled or severe cardiovascular disease.
  5. Subjects with active or active .
  6. Known allergy to the study drug or its components.
  7. Pregnant or lactating women.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    GFH276

    GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

    Drug: GFH276

Interventions

  • DrugGFH276

    GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

07

What researchers measure

Primary outcomes

  1. Phase Ia:The incidence and severity of AEs and SAEs

    The incidence and severity of AEs and SAEs

    Time frame: 48 months

  2. Phase Ia:The incidence of DLT events

    The incidence of DLT events

    Time frame: 21 days

  3. Phase Ib:The incidence and severity of AEs and SAEs

    The incidence and severity of AEs and SAEs

    Time frame: 48 months

  4. Phase II:Overall response rate (ORR)

    Aassessed by investigators according to RECIST 1.1

    Time frame: about 48 months

  5. Efficacy endpoints

    Duration of response (DoR)

    Time frame: about 48 months

Secondary outcomes

  1. Peak Plasma Concentration(Cmax)

    Time frame: about 48 months

  2. DCR

    he percentage of patients who achieved CR, PR and SD

    Time frame: about 48 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 22 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Jul 2027, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 30, 2025
StartActual
Sep 18, 2025
Primary completionEst.
Jul 30, 2027was Sep 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Sun-Yat sen university cancer center is now Recruiting
Nov 16, 2026
Start date
Sep 22, 2025→Sep 18, 2025 (actual)
Nov 16, 2026
Primary completion
Sep 22, 2027→Jul 30, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Sun-Yat sen university cancer center is now Recruiting
    Start date Sep 22, 2025→Sep 18, 2025 (now actual)
    Primary completion Sep 22, 2027→Jul 30, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07198321
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Sep 18, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

peng, PM
Contact
ytpeng@genfleet.com
021-50781198
li zhang, MD
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GFH276

Start the discussion